ES2162917T3 - Mejoras en o relativas al suministro de peptidos. - Google Patents

Mejoras en o relativas al suministro de peptidos.

Info

Publication number
ES2162917T3
ES2162917T3 ES95918692T ES95918692T ES2162917T3 ES 2162917 T3 ES2162917 T3 ES 2162917T3 ES 95918692 T ES95918692 T ES 95918692T ES 95918692 T ES95918692 T ES 95918692T ES 2162917 T3 ES2162917 T3 ES 2162917T3
Authority
ES
Spain
Prior art keywords
polypeptide
union
biological effect
peptides
relating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918692T
Other languages
English (en)
Inventor
Donald Leonard Nicholas Cardy
Frank Joseph Carr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biovation Ltd
Original Assignee
Biovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9409643A external-priority patent/GB9409643D0/en
Application filed by Biovation Ltd filed Critical Biovation Ltd
Application granted granted Critical
Publication of ES2162917T3 publication Critical patent/ES2162917T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE DESCRIBE UN POLIPEPTIDO QUIMERICO QUE COMPRENDE UNA PORCION DE ENLACE CON ESPECIAL AFINIDAD DE UNION POR UN COMPONENTE SUPERFICIAL DE CELULA DIANA EUCARIOTICA Y UNA PORCION EFECTORA QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS CAPAZ DE TENER UN EFECTO BIOLOGICO; CON ESTO LA UNION DEL POLIPEPTIDO AL COMPONENTE CELULAR DE SUPERFICIE INDUCE LA INTERNALIZACION DE AL MENOS LA PORCION EFECTORA DE MANERA QUE PERMITE QUE LA SECUENCIA DE AMINOACIDO EJERCE SU EFECTO BIOLOGICO, JUNTO CON UNA VACUNA QUE COMPRENDE EL POLIPEPTIDO QUIMERICO DE LA INVENCION; Y UN METODO DE MODULACION DE LA RESPUESTA INMUNOLOGICA DE UN SUJETO ANIMAL O HUMANO.
ES95918692T 1994-05-13 1995-05-15 Mejoras en o relativas al suministro de peptidos. Expired - Lifetime ES2162917T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9409643A GB9409643D0 (en) 1994-05-13 1994-05-13 Recombinant antibodies for delivery of immunodominant peptides
GB9417461A GB9417461D0 (en) 1994-05-13 1994-08-31 Recombinant antibodies for delivery of immunodominant peptides

Publications (1)

Publication Number Publication Date
ES2162917T3 true ES2162917T3 (es) 2002-01-16

Family

ID=26304881

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918692T Expired - Lifetime ES2162917T3 (es) 1994-05-13 1995-05-15 Mejoras en o relativas al suministro de peptidos.

Country Status (10)

Country Link
US (2) US20020106370A1 (es)
EP (1) EP0759944B1 (es)
JP (1) JPH10500670A (es)
AT (1) ATE204300T1 (es)
AU (1) AU701302B2 (es)
CA (1) CA2190101A1 (es)
DE (1) DE69522216T2 (es)
DK (1) DK0759944T3 (es)
ES (1) ES2162917T3 (es)
WO (1) WO1995031483A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
AU721927B2 (en) * 1995-12-22 2000-07-20 Immunomedics Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
GB9712892D0 (en) * 1997-06-20 1997-08-20 Eclagen Ltd Identification of mhc binding peptides
US7314632B1 (en) 1997-07-11 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin A-like chimeric immunogens
US20030054012A1 (en) * 2000-05-12 2003-03-20 Fitzgerald David J. Pseudomonas exotoxin a-like chimeric immunogens for eliciting a secretory iga-mediated immune response
DE69831951T2 (de) * 1997-07-11 2006-07-27 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pseudomonas exotoxin a-ähnliche chimäre immunogene
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60043070D1 (de) 1999-10-22 2009-11-12 Genentech Inc Proteine-abgabe durch polare epithelzellen schichte
GB9930616D0 (en) 1999-12-24 2000-02-16 Mathilda & Terence Kennedy Ins Activation and inhibition of the immune system
EP1379550B1 (en) 2000-12-21 2009-03-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES A chimeric protein comprising non-toxic pseudomonas exotoxin a and type iv pilin sequences
GB0102145D0 (en) 2001-01-26 2001-03-14 Scancell Ltd Substances
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
DE10259713A1 (de) * 2002-12-19 2004-07-08 Johannes-Gutenberg-Universität Mainz Verfahren zur Expressionsstabilisierung und Verbesserung der spezifischen Effektorfunktion von Einzelketten-Antigenerkennenden genetischen Konstrukten (scARC) und entsprechend mutierten MDM2-Protein spezifischen scT-Zell Rezeptoren
EA011859B9 (ru) 2004-01-05 2013-07-30 Емд Лексиген Ресерч Сентер Корп. Соединения для адресной доставки препарата к ткани или органу-мишени
CA2583202A1 (en) * 2004-10-04 2006-04-27 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of macromolecules
US7611714B2 (en) 2004-10-04 2009-11-03 Trinity Biosystems, Inc. Methods and compositions for immunizing against Pseudomonas infection
SI1699826T1 (sl) * 2005-01-05 2009-08-31 Ngsges M B H F Star Biotechnol Sintetske imunoglobulinske domene z vezavnimi lastnostmi, konstruiranimi v regijah molekule, različnih od regij, ki določajo komplementarnost
ES2971647T3 (es) 2005-04-15 2024-06-06 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9963510B2 (en) * 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
WO2007048022A2 (en) * 2005-10-21 2007-04-26 Alexion Pharmaceuticals, Inc. Antibody-polypeptide fusion proteins and methods for producing and using same
WO2007067597A2 (en) * 2005-12-05 2007-06-14 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of binding partners
EP1966246A4 (en) * 2005-12-05 2010-01-06 Trinity Biosystems Inc METHOD AND COMPOSITIONS FOR NEEDLE-FREE ADMINISTRATION OF ANTIBODIES
US20090305978A1 (en) * 2006-03-16 2009-12-10 Trinity Biosystems, Inc. Methods for increasing the size of animals using needleless delivery constructs
GB0605735D0 (en) * 2006-03-22 2006-05-03 Immunobiology Ltd Composition and method for mediating an immune response
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
US20090092660A1 (en) * 2006-08-09 2009-04-09 Trinity Biosystems, Inc. Methods and compositions for needleless delivery of particles
GB0706070D0 (en) 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
JP5602625B2 (ja) 2007-06-26 2014-10-08 エフ−スター ビオテヒノロギッシェ フォルシュングス− ウント エントヴィッケルングスゲゼルシャフト ミット ベシュレンクテル ハフツング 結合物質のディスプレイ
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN102405230A (zh) 2009-04-22 2012-04-04 默克专利有限公司 具有修饰的FcRn结合位点的抗体融合蛋白
US20110117087A1 (en) 2009-10-26 2011-05-19 Reinhard Franze Method for the production of a glycosylated immunoglobulin
SG10201703425RA (en) 2011-05-21 2017-05-30 Macrogenics Inc Cd3-binding molecules capable of binding to human and non-human cd3
US9908938B2 (en) 2013-03-14 2018-03-06 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor and an antigen expressed by a cell infected by a virus and uses thereof
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
CN106604740A (zh) 2014-02-14 2017-04-26 宏观基因有限公司 用于治疗血管化癌症的改进的方法
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668255A (en) * 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5283323A (en) * 1985-08-07 1994-02-01 The United States Of America As Represented By The Department Of Health And Human Services Method of producing immune response
JPH03504975A (ja) * 1988-06-14 1991-10-31 セル―エスシーアイ　コーポレイション 異種官能性細胞免疫剤、それを含有するワクチン及びその使用方法
US6172197B1 (en) * 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
CA2077277A1 (en) * 1991-09-09 1993-03-10 John J. Donnelly Cellular immunity vaccines from bacterial toxin-antigen conjugates
CA2081952A1 (en) * 1991-11-08 1993-05-09 John J. Donnelly Recombinant dna sequences and plasmids for cellular immunity vaccines from bacterial toxin-antigen conjugates, and methods of their use
US5597569A (en) * 1993-10-25 1997-01-28 Bristol-Myers Squibb Company Bryodin 2 a ribosome-inactivating protein isolated from the plant Bryonia dioica

Also Published As

Publication number Publication date
WO1995031483A1 (en) 1995-11-23
EP0759944B1 (en) 2001-08-16
DK0759944T3 (da) 2001-11-26
AU2452195A (en) 1995-12-05
JPH10500670A (ja) 1998-01-20
DE69522216T2 (de) 2002-05-02
AU701302B2 (en) 1999-01-21
US20020106370A1 (en) 2002-08-08
EP0759944A1 (en) 1997-03-05
CA2190101A1 (en) 1995-11-23
DE69522216D1 (de) 2001-09-20
ATE204300T1 (de) 2001-09-15
US20060099216A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
ES2162917T3 (es) Mejoras en o relativas al suministro de peptidos.
NZ330897A (en) Human trk receptors and neurotropic factor inhibitors
DE3650751D1 (de) Antikörper gegen Saugetier-Interleukin-4 und Peptide verwendbar als Antigenen für deren Herstellung
ES2077666T3 (es) Proteina de union a fibronectina y su preparacion.
BR9713294A (pt) "anticorpos contra proteìna relacionada a hormÈnio de paratiróide humano"
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
NZ512083A (en) Methods of increasing lean tissue mass using OB protein compositions
ATE175417T1 (de) Leadersequenz zur induzierung einer posttranslationalen modifikation von polypeptiden in bakterien, sowie dafür kodierendes gen
ES548617A0 (es) Procedimiento para disociar peptidos y proteinas en el enla-ce metionilo
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
ATE360695T1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE185148T1 (de) Lipopeptide, t-cytotoxische lymphocyte aktivierend, und deren verwendung als vakzine
DE69529272T2 (de) MONOKLONALER ANTIKÖRPER GEGEN DAS HUMANE Mx-PROTEIN MxA
ATE252153T1 (de) Rekombinanter birnavirusimpfstoff
BR0207905A (pt) Protamina modificada com imunogenicidade reduzida
ES2074983T3 (es) Procedimieto para el aislamiento de proteinas de membranas basales a partir de tejidos humanos y animales.
BR0303362A (pt) Composição e método para melhorar uma resposta imune em um animal, método para distribuir uma proteìna de carga em uma célula de animal, célula viva geneticamente modificada, e, método para a construção de uma proteìna de fusão para melhorar a resposta imune em um animal
ES2091159B1 (es) Antigeno recombinante, rsm14, procedente de schistosoma mansoni, su obtencion y utilizacion.
AR014811A1 (es) Un peptido que enlaza anticuerpos con elevados niveles de pacientes esquizofrenicos, un ensayo para el diagnostico de la esquizofrenia y un equipopara el uso en el diagnostico de esquizofrenia
ES2054942T3 (es) Procedimiento para la determinacion de fructuosaminas.
ES2163921T3 (es) Substancia con actividad renina que contiene prorrenina humana y los anticuerpos contra el profragmento de prorrenina.
ES2063223T3 (es) Anticuerpos contra secuencias de aminoacidos muy conservadas de sustancias inmunogenas, procedimiento para la preparacion de estos anticuerpos, asi como su utilizacion en inmunoensayos.
ATE129744T1 (de) Rekombinantes c-terminal alpha amidatierungsenzym von menschlischem thyroidursprung.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 759944

Country of ref document: ES